Import tariffs have become the priority trade issue since President Donald Trump took office on January 20, 2025, with a wide variety of measures…
- New White House Executive Order to Establish “Most-Favored-Nation” Drug Pricing
- US Tariffs and the Life Science industry – an update
- The Healthcare Agenda of Germany’s New CDU/SPD Coalition Government – A Point-by-Point Analysis of Key Policies and Their Potential Implications for Pharma and Med-Tech Companies
- Switzerland’s Therapeutic Products Act Revision: Industry Stakeholders Show Positive Support
- European Commission Proposes Act to Secure Critical Medicines Supply but has Wider Ambitions for Improved Accessibility of Other Medicinal products by Creating a Framework for Collaborative Procurement
- The Impact of Tariffs on the Life Sciences Industry
- European Health Data Space Regulation Published – What’s Next?
- Hungary to introduce important changes to named patient reimbursement
On 5th March 2025, the European Health Data Space (EHDS) Regulation was officially published in the Official Journal of the European Union. The EHDS…
In Hungary, certain decisions on named patient reimbursement of medicinal products and medical aids will be made by a public benefit foundation in addition…
Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…
On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…
In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…
The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…
As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…
As already well noted on this blog, on 26 April 2023 the European Commission published a set of…